Results 71 to 80 of about 539,046 (150)

Reduced synaptic vesicle protein 2A in extracellular vesicles and brains of Alzheimer's disease: associations with Aβ, tau, synaptic proteins and APOE ε4. [PDF]

Transl Neurodegener
Alzheimer's disease (AD) is characterized by accumulation of amyloid-β (Aβ) plaques, tau neurofibrillary Tangles and synaptic dysfunction. The aim of this study was to map the distributions of synaptic vesicle protein 2A (SV2A) and other synaptic ...
Nussbaumer J, Barve A, Zufferey V, Espourteille J, Kirabali T, Konietzko U, Razansky D, Rominger A, Nordberg A, Buée L, Colin M, Nitsch RM, Hock C, Richetin K, Ni R.   +14 more
europepmc   +3 more sources

Transcranial Magnetic Stimulation as a Translational Biomarker in Early‐Phase Anti‐Seizure Medication Development: A Randomized, Double‐Blind, Placebo‐Controlled Study in Generalized Epilepsy

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 673-683, September 2026.
One‐third of epilepsy patients remain treatment‐resistant, underscoring the need for novel anti‐seizure medications (ASMs) and reliable biomarkers of central target engagement. Cortical hyperexcitability is a hallmark of epilepsy, making excitability a valuable pharmacodynamic biomarker for early‐phase drug development supporting go/no‐go decision ...
Catherine M. E. de Cuba, Titia Q. Ruijs, Annika A. de Goede, Robert J. Doll, Maria Juachon, Michel J. A. M. van Putten, Geert Jan Groeneveld, Jules A. A. C. Heuberger   +7 more
wiley   +1 more source

Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A

Nature Communications
More than one percent of people have epilepsy worldwide. Levetiracetam (LEV) is a successful new-generation antiepileptic drug (AED), and its derivative, brivaracetam (BRV), shows improved efficacy.
Atsushi Yamagata, Kaori Ito, Takehiro Suzuki, Naoshi Dohmae, Tohru Terada, Mikako Shirouzu   +5 more
doaj   +1 more source

Ranking of antiseizure medications in a panel of focal seizure models predicts their comparative efficacy in clinical add‐on trials in drug‐resistant focal epilepsy

Epilepsia, Volume 67, Issue 7, Page 3719-3737, July 2026.
Abstract Objective Most antiseizure medications (ASMs) have been discovered by testing in animal models, which are generally thought to predict antiseizure activity in patients. However, it is not known whether any of these models (or a combination of models) can predict whether a novel ASM exhibits higher clinical efficacy in focal drug‐resistant ...
Wolfgang Löscher, Pavel Klein
wiley   +1 more source

Synaptic Vesicle Glycoprotein 2A (SV2A) as a Measure of Synaptic Plasticity in Animal Models of Depression [PDF]

, 2019
Depression associeres med synapsetab grundet en nedregulering af vigtige proteiner involveret i opretholdelsen af synapser. Et foreslået indirekte mål for synapsedensitet er det præsynaptiske protein SV2A.
Ali, Saba, Labrouzi, Mariam
core  

SGIP1α functions as a selective endocytic adaptor for the internalization of synaptotagmin 1 at synapses

Molecular Brain, 2019
Proper sorting of exocytosed synaptic vesicle (SV) proteins into individual SVs during endocytosis is of the utmost importance for the fidelity of subsequent neurotransmission.
Sang-Eun Lee, Soomin Jeong, Unghwi Lee, Sunghoe Chang   +3 more
doaj   +1 more source

A consensus roadmap for post‐traumatic epilepsy: Clinical biomarkers, research priorities, policy barriers, and pathways to interventional trials

Epilepsia, Volume 67, Issue 7, Page 3281-3299, July 2026.
Abstract Understanding the mechanisms underlying post‐traumatic epilepsy (PTE) following traumatic brain injury (TBI), and developing strategies to prevent or modify its progression, has been the focus of large collaborative efforts within the epilepsy and TBI research communities for over a decade.
Elisa R. Zanier, Ilaria Lisi, Elaine K. O'Loughlin, Federico Moro, Edilberto Amorim, David L. Brody, Daniel J. Correa, Dominique Duncan, Pavel Klein, Firas H. Kobeissy, Wolfgang Löscher, Edward J. Needham, Asla Pitkänen, Mary Jo Pugh, Jack Somers, Annamaria Vezzani, Amy K. Wagner, Laura S. Lubbers, International Conference on PTE Attendees, Denes Agoston, Edilberto Amorim, Sneha Anand, Hibah Awwad, Ginevra Bayon, Naima Belhachemi, Akash Bera, Costanza Bertani, Guido Bertolini, David L. Brody, Serena Brusatori, Francesca Buffelli, Aurora Chiapperini, Mara Chioccola, Severn Churn, Daniel J. Correa, Ramon Diaz‐Arrastia, Chris Dulla, Dominique Duncan, Chiara Ferlito, Aristea Galanopoulou, Angela Galic, Heidi Matos Galicia, Bin Gu, William Haskins, Victoria Johnson, Nigel Jones, Lowie Joseph, Pavel Klein, Firas Kobaissy, Ilaria Lisi, David Loane, Luther Loose, Laura S. Lubbers, Wolfgang Löscher, Edoardo Mazzone, Melissa Miller, Federico Moro, Edward J. Needham, Irma Wati Ngadimon, Terence O'Brien, Elaine K. O'Loughlin, Asla Pitkanen, Mary Jo Pugh, Teresa Giovanna Ravizza, Giuseppe Remuzzi, Massimo Rizzi, Rossella Di Sapia, Tawfeeq Shekh‐Ahmad, Doug Smith, Jack Somers, Kevin Staley, Francesca Tribuzio, Alexandra Ulyanova, Gloria Vegliante, Annamaria Vezzani, Joost Wagenaar, Amy K. Wagner, Kevin W. Wang, Justin Weppner, Peter J. West, Karen Wilcox, John Wolf, Elisa R. Zanier   +82 more
wiley   +1 more source

Reduction in hippocampal cholinergic neurostimulating peptide enhances memory impairment in AppNL‐G‐F KI mice

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Whether cholinergic activity in the septohippocampal network affects cognitive dysfunction via hippocampal cholinergic neurostimulating peptide (HCNP) in Alzheimer's pathogenesis remains unclear. METHODS An Alzheimer's pathogenesis by mutation in amyloid‐beta precursor protein gene (AppNL‐G‐F) knock‐in (KI) and HCNP precursor ...
Yo Tsuda, Yuta Madokoro, Kengo Suzuki, Takuya Ooba, Toyohiro Sato, Yuto Uchida, Itsumi Nagai‐Arakawa, Takashi Saito, Hideaki Hara, Hideki Hida, Noriyuki Matsukawa   +10 more
wiley   +1 more source

Redirecting Alzheimer's disease therapeutics: Multitarget drugs and complementary non‐pharmacological strategies

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder driven by intersecting pathological processes. Persistent attrition in AD drug‐development pipelines highlights the limited clinical impact of single‐target therapies and has increased interest in multi‐target approaches acting on shared biological hubs.
Humberto Martínez‐Orozco, Jesús Andrade‐Guerrero, Nelly Jovana Pastén‐Castrejón, Chryslaine Rodríguez‐Tanty, Sofía Y Diaz‐Miranda   +4 more
wiley   +1 more source

Severe Cutaneous Adverse Reactions Associated With Newer‐Generation Antiseizure Medications: A Real‐World Pharmacovigilance Study Based on FAERS and JADER

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
A cross‐database analysis of FAERS and JADER confirmed lamotrigine and zonisamide as the dominant SJS/TEN/DRESS risk drivers across both systems. After polytherapy adjustment, eslicarbazepine (DRESS, ROR 10.41) and levetiracetam emerged as reproducible novel signals warranting clinical attention. SJS/TEN onset concentrated within 4 weeks, whereas DRESS
Longfei You, Dong Zhang, Zhihua Cheng, Yinbao Qi, Ruobing Qian   +4 more
wiley   +1 more source